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ABSTRACT
Recently the FDA authorized one direct-to-consumer genetic testing (DTC-GT)
company to begin reporting certain genetic variants in the BRCA1 and BRCA2 genes.
Pathogenic variants in these genes confer lifetime risks for breast and ovarian cancer in
women as high as 87% and 62%, respectively. Historically, genetic testing for these
mutations has been offered in a clinical setting where genetic counseling is part of the
testing process. Genetic counseling is not routinely a part of DTC-GT, raising concern
that those undergoing DTC-GT for BRCA1/2 mutations may not fully understand what is
being tested, the implications of results, or that they may experience psychological
distress from receiving an unexpected result. The goal of our study was to assess how
BRCA1/2 mutation carriers who went through clinical genetic testing feel about DTC-GT
for BRCA1/2 mutations. Results indicate that most respondents are in favor of DTC-GT
for BRCA1/2 mutations being available, as it increases access to this empowering
information. However, most participants also had concerns about DTC-GT, with most
worried about false negatives and lack of counseling/support for mutation-positive
consumers. Additionally, respondents would be more likely to choose DTC-GT in a
scenario where clinical testing is difficult to access or when they had negative
perceptions of certain aspects of their own genetic testing experience. These findings
suggest that an enhanced DTC-GT model which incorporates pre- and/or post-test
counseling by a certified genetic counselor could be a viable option that would have
support from the BRCA-mutation carrier population.

iv

TABLE OF CONTENTS
ACKNOWLEDGEMENTS............................................................................................ iii
ABSTRACT .................................................................................................................. iv
LIST OF TABLES ......................................................................................................... vi
LIST OF FIGURES ...................................................................................................... vii
CHAPTER1: BACKGROUND ....................................................................................... 1
CHAPTER 2: BRCA1 and BRCA2 Mutation-Positive Patient Perspectives on Direct-toConsumer Genetic Testing for BRCA Mutations ........................................................... 18
REFERENCES ............................................................................................................. 48
APPENDIX A: Web-Based Questionnaire .................................................................... 54

v

LIST OF TABLES
Table 2.1 Demographic characteristics of survey participants ........................................ 30
Table 2.2 Previous genetic testing experience................................................................ 31
Table 2.3 Satisfaction with previous genetic testing....................................................... 32
Table 2.4 DTC-GT compared to clinical testing ............................................................ 34

vi

LIST OF FIGURES
Figure 2.1 BRCA1/2 carrier preference between DTC-GT and
clinical genetic testing in different scenarios ................................................................. 35
Figure 2.2 BRCA1/2 carrier support and concerns about DTC-GT
for BRCA1/2 mutations ................................................................................................. 36

vii

CHAPTER 1
BACKGROUND
1.1 Direct-to-consumer genetic testing
Genetic testing has evolved rapidly since it was first utilized in the 1960s. Over
the past few decades, more tests have become available and are being offered at a lower
price than previously. Historically, genetic testing has been ordered by physicians,
genetic counselors, or other healthcare providers to evaluate future risk of a specific
disease, establish a diagnosis, or aid in medical management of an existing condition. In
this setting, the healthcare provider determines which genetic test fits the patient’s needs
and desires, collects the sample, sends it to a laboratory to be analyzed, and then delivers
the results to the patient. Typically, this process also involves some form of genetic
counseling—performed by either the ordering provider or a board-certified genetic
counselor. Genetic counseling helps the patient understand the test itself, their result, and
what it means for their health, but can also have a role in assessing and managing the
patient’s psychological response.
Direct-to-consumer genetic testing (DTC-GT) is a process by which individuals
can order genetic testing without involvement of their personal physician or healthcare
provider. Since DTC-GT first entered the market in the mid-2000s, it has grown quickly
and is expected to continue to grow at a rate of 20% over the next eight years (“DirectTo-Consumer…”, Credence Research). DTC-GT can be ordered by any adult via the
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internet, phone, or over-the-counter (Wesselius & Zeegers, 2013). Once a person orders
the test, a collection kit is usually sent to their home. A saliva sample is then sent back to
the company for analysis. Results are typically reported back to the consumer within 8
weeks. Information provided through DTC-GT can include ancestry, physical traits,
genetic disease risk, and carrier status (Wesselius & Zeegers, 2013). While the process up
to this point usually does not involve the patient’s healthcare provider, some patients may
share their results with their provider, and some DTC-GT companies offer post-test
genetic counseling to consumers. However, research has shown that few customers
utilize post-test genetic counseling (Koeller et al., 2017). Additionally, the cost of DTCGT has significantly decreased since it first became available, from around $1,000 in
2007 to approximately $100-150 today (Allyse et al., 2018). This allows many patients to
order DTC-GT without relying on health insurance.
1.2 Potential benefits of direct-to-consumer genetic testing
DTC-GT has several potential advantages and benefits over clinical genetic
testing, which have contributed to its rapid growth over the past decade. One of the main
benefits is accessibility. Certain information that is offered through DTC-GT, such as
carrier status for genetic conditions, or testing for alleles associated with increased risk
for certain conditions, can otherwise only be ordered through genetic professionals.
However, there is currently a shortage of geneticists and genetic counselors in the United
States, making it difficult for many people to have access to their services (Hoskovec et
al., 2018). In some areas, people may have to drive hours to meet with a geneticist or
genetic counselor, and others may have to wait months to get an appointment. With DTC-
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GT, anyone who has access to a phone or to the internet can obtain certain genetic
information without needing access to a genetics professional.
Additionally, cost is a major issue for many people who desire genetic
information. The 23andMe health and ancestry kit, for example, typically costs about
$200USD, while a carrier screening panel that screens for a similar number of conditions
from a clinical lab may cost thousands of dollars. For those with no or limited insurance
coverage, DTC-GT may be a more feasible option than pursuing clinical genetic testing.
Proponents of DTC-GT also argue that the increased accessibility of genetic
information with DTC-GT will allow the general population to be more engaged in their
healthcare, more autonomous in health-related decision-making, and more
knowledgeable about hereditary disease. By providing people with information about
their genetic susceptibility to disease, DTC-GT empowers patients to make informed
health-related decisions. One recent study on DTC-GT found that after receiving results,
59% of DTC-GT customers surveyed said that their test results would influence how they
manage their health, and 65% said they felt more in control of their health after receiving
results (Roberts et al., 2017). Many healthcare providers also agree that information
provided by DTC-GT can be useful information for consumers, especially when it comes
to testing for hereditary cancer syndromes. For example, 86% of providers surveyed in
one study agreed that DTC-GT for hereditary breast cancer provides clinically useful
information (Giovanni et al., 2010). Research has also shown that individuals who learn
that they are at high risk for cancer after genetic testing often find the information useful
and empowering (Crotser and Dickerson, 2010). In a survey of people who learned of
their risk for hereditary cancer through DTC-GT, 97% of consumers were glad they
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learned of their increased risk for cancer, and almost every participant who learned of
their increased risk for cancer for the first time through DTC-GT made plans to consult
specialists, undergo increased cancer screening, or even pursue prophylactic surgery
(Francke et al., 2013).
1.3 Potential risks of direct-to-consumer genetic testing
The rapid growth and utilization of DTC-GT has raised concern among some
health professionals about the possible risks of this type of unsupervised genetic testing.
Some genetic test results can be confusing, upsetting, or life-altering for patients.
Concerns include the incorrect comprehension or use of results by patients or that results
could cause unnecessary worry and anxiety in patients (Annes, Giovanni, & Murray,
2010; Kalokairinou, Howard & Borry, 2014; “What are the benefits…”, 2018). Those
patients who do not have high health literacy or a basic understanding of genetics may
not understand the complexity of genetic information that is reported via DTC-GT or
even understand that information they receive from DTC-GT could have a significant
impact on their lives. For example, it has been shown that people who ordered DTC-GT
report lower levels of confidence in their genetic knowledge and understanding after they
go through the process of DTC-GT than they did before undergoing testing, indicating
that patients may not fully appreciate the complexities of genetic risk and inheritance
prior to ordering DTC-GT (Carere et al., 2016). Additionally, consumer comprehension
of results from DTC-GT varies significantly based on demographic factors such as age
and level of education (Ostergren et al., 2015). Another major concern is that DTC-GT
could burden patients with unnecessary costs as the result of inappropriate follow-up care
after misinterpreted test results (Annes, Giovanni, & Murray, 2010). One study found that
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clinical follow-up for DTC-GT results, including referral to physicians and/or a genetic
counselor, referral to a specialist, and referral for additional diagnostic testing ranged
from $40 to over $20,000 (Giovanni et al., 2010). This supports the concern that DTCGT could result in a high financial burden on the patient and/or healthcare system,
especially when DTC-GT results are misinterpreted or have limited clinical utility.
The potential for psychological stress is also a concern with DTC-GT. In one
recent study, close to 40% of people who ordered DTC-GT said they did not consider the
possibility that they could get information they did not want from the test (Roberts et al.,
2017). For example, some consumers may not want to know that they carry a variant that
is associated with late-onset Alzheimer’s Disease, which is reported by some DTC-GT
services. Knowing this information could cause anxiety as well as fear that they might
develop Alzheimer’s, for which there are no preventative measures or cure. While these
sorts of concerns are routinely discussed when genetic testing is ordered through a health
professional, many consumers likely do not consider this possibility when ordering DTCGT. In a case report published by Dohany and colleagues (2012), one patient
unexpectedly found out via DTC-GT that she had an Ashkenazi Jewish founder mutation
that significantly increased her risk for breast and ovarian cancer. This patient stated that
this was not information she had been prepared or wanted to receive, and it caused her
psychological distress, resulting in constant worrying and loss of sleep. She also had
trouble understanding the meaning of her results and how she should proceed with her
management (Dohany et al., 2012). Although this particular patient eventually sought
genetic counseling, which alleviated much of her anxiety and confusion, it appears that
the majority of people who receive DTC-GT do not discuss their results with a healthcare
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provider. In fact, one previous study found that only 4% of people who went through
DTC-GT planned on scheduling an appointment with a genetic counselor to discuss the
results (Koeller et al., 2017).
The American College of Medical Genetics and Genomics (ACMG) has
published a position statement with recommendations regarding DTC-GT.
Recommendations include involving a professional when ordering the test and when
delivering and interpreting results, inclusion of family history when calculating disease
risk, and clearly stating what DTC-GT can and cannot definitively tell the consumer
about health and disease risk (ACMG Board of Directors, 2016). However, many
consumers do not involve healthcare providers at all in the DTC-GT process, and most
DTC-GT companies do not take family history into account when calculating disease
risk. The position of the National Society of Genetic Counselors is that consumers have a
right to make an informed decision regarding DTC-GT, and companies offering DTC-GT
have a responsibility to offer genetic counseling services or referral to such services
(NSGC, 2015).
1.4 FDA regulation of direct-to-consumer genetic testing
The U.S. Food and Drug Administration (FDA) began regulating DTC-GT in
2010, after an investigation by the U.S. Government Accountability Office concluded
that DTC-GT companies used deceptive marketing and gave misleading test results that
exaggerated the utility of the information provided by the test results in relation to health
(Allyse et al., 2018). Additionally, other critics of DTC-GT were concerned that the
informed consent process for testing was unclear and that consumers may not fully
understand the implications of their test results (Skirton et al., 2012). This investigation

6

prompted the FDA to send warning letters to the five largest DTC-GT companies
(23andMe, Navigenics, deCODE Genetics, Knome, and Illumina) in June 2010,
informing them that their health-related testing services needed FDA approval prior to
marketing them to the general public. The FDA sent another letter in 2013 to several
DTC-GT companies, including 23andMe, that had failed to comply with the requests
made by the FDA in 2010. In this 2013 letter, the FDA ordered them to stop marketing
and selling their DTC-GT services for health-related information, such as breast cancer
risk, until appropriate studies on the validity had been performed and the FDA approved
them (Allyse et al., 2018). The FDA cited concern that people may make drastic healthrelated decisions based on their test results, particularly results related to breast cancer
risk, and that there was no evidence that the genetic testing being performed was
analytically or clinically valid (Annas and Elias, 2014). This was a major step in the
regulation of DTC-GT.
Over the next few years following the FDA shutdown of DTC-GT, 23andMe
worked to ensure the validity of its tests as well as conduct research on user
comprehension of results (Allyse et al., 2018). The first FDA approval of a DTC-genetic
test came in 2015, when 23andMe received approval to market a test to screen for carriers
of the genetic disease Bloom Syndrome (Allyse et al., 2018). DTC companies were then
approved to offer carrier screening for additional diseases as well, and in 2017 the FDA
authorized DTC-GT companies to begin offering tests for “genetic health risk” (Allyse et
al., 2018). 23andMe was the first company to begin marketing this type of test, offering
reports for some treatable or preventable diseases, such as celiac disease and hereditary
hemochromatosis, as well as some potentially life-shortening, incurable disorders such as
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Alzheimer’s disease and Parkinson’s disease. The reports for non-curable diseases such
as Alzheimer’s and Parkinson’s are “opt-in”, meaning that customers will not be shown
their results unless they choose to see them and those that do choose to see them must
read a disclaimer prior to being shown their results. Additionally, for each genetic health
risk report, the company makes clear that receiving a result indicating that you are at high
risk to develop a certain disease does not mean you will definitely develop the disease. In
2018, the FDA gave approval to 23andMe to begin opt-in reporting on certain variants in
breast cancer susceptibility genes BRCA1 and BRCA2 (US Food and Drug
Administration, 2018). Most recently, in January of 2019, the FDA gave clearance for
23andMe to begin reporting two additional cancer risk variants in the MUTYH gene,
which is associated with a hereditary colorectal cancer syndrome.
Some research has been done investigating public opinion of expanded access and
government regulation of DTC-GT. In one study, people who sought DTC-GT were
generally in favor of expanded access and less government regulation (Gollust et al.,
2017). However, consumers who believed their results indicated that they were at higher
risk for a genetic disease and consumers who reported negative emotions after receiving
their results were less likely to support expanded access to DTC-GT without involving a
healthcare professional (Gollust et al., 2017).
1.5 Breast cancer and BRCA1 and BRCA2 mutations
Breast cancer is the most common cancer in the world, affecting 1 in 8 women in
their lifetime and is the leading cause of cancer-related death in women. It is estimated
that about 10% of breast cancer is caused by familial mutations in single genes.
Mutations in the BRCA1 and BRCA2 genes are thought to be responsible for about 50%
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of cases of hereditary breast and ovarian cancer (HBOC), and about 5-6% of all breast
cancers (Campeau et al., 2008). BRCA1/2 mutations are highly penetrant and inherited in
an autosomal dominant fashion. This means that a mutation in only one copy of the
BRCA1 or BRCA2 gene is sufficient to cause an increased cancer risk. Additionally, each
person with a BRCA1/2 mutation has a 50% chance of passing the mutation on to each of
their children.
The lifetime risk of a woman with a BRCA1/2 mutation developing breast cancer
is estimated to be between 38% and 87%, compared to 12% in the general population. A
woman with a BRCA1/2 mutation also has a lifetime ovarian cancer risk of 16.5% to
62%, compared to 1-2% in the general population (Petrucelli, Daly & Pal, 2016). Men
with BRCA1 or BRCA2 mutations are also at an increased risk for breast cancer. In the
general population, about 0.1% of males will develop breast cancer while 1.2% of men
with a BRCA1 mutation and 8.9% of men with a BRCA2 mutation will develop breast
cancer in their lifetime (Petrucelli, Daly & Pal, 2016). Additionally, people with
BRCA1/2 mutations are also at increased risk to develop other types of cancers. Men with
BRCA1/2 mutations have an 8-20% lifetime risk of developing prostate cancer, compared
to a 6% chance in the general population (Petrucelli, Daly & Pal, 2016). The risk for
pancreatic cancer is also increased in individuals that carry a mutation in BRCA1/2.
1.6 Genetic testing for BRCA1 and BRCA2 mutations
Analysis of the BRCA1 and BRCA2 genes is one of the oldest and most wellstudied uses of clinical genetic testing for hereditary cancer risk. Indications for genetic
testing of BRCA1/2 mutations include a strong family history of breast and/or ovarian
cancer, unusual presentations of breast cancer (for example, a male with breast cancer),
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early-onset breast cancer, a mutation previously identified in the family, or Ashkenazi
Jewish ancestry with any breast cancer family history, as the frequency of BRCA1/2
mutations is higher in this population (Hampel et al., 2015). Genetic testing for BRCA1/2
mutations usually begins with an in-depth discussion of personal and family history and
risk assessment. If the decision to order genetic testing is made, the healthcare provider
typically helps the patient choose between testing for mutations in BRCA1/2 only or
testing for mutations in a panel of genes (including more than just BRCA1/2) that are
known to be associated with hereditary breast and/or ovarian cancer. Targeted testing for
known familial mutations can also be done. If a patient tests positive for a BRCA1 or
BRCA2 mutation, professional guidelines outline a number of actions that can be taken to
reduce risk or improve detection of breast and ovarian cancer, including increased
screening (such as mammograms and breast MRI), risk-reduction agents such as
tamoxifen, and in some cases prophylactic surgery, such as bilateral mastectomy or
salpingo-oophorectomy. It is also recommended that women who undergo testing for
BRCA1/2 mutations receive counseling about cancer risk, management techniques, and
psychosocial issues, as deciding to undergo prophylactic surgery can be stressful and
significantly impact quality of life (National Comprehensive Cancer Network, 2017).
Testing positive for a BRCA1 or BRCA2 mutation can have a psychological
impact on a patient. In one study, 75% of patients reported that their worry increased
after receiving their positive test results. The patients reported anxiety over the high
possibility of getting cancer and worry about passing on the mutation to their children
(Prospero et al., 2001). Other studies have also found that patients who receive a positive
test result tend to experience increased levels of anxiety and depression compared to
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patients with a negative test result (Lodder et al., 2001; Wagner et al., 2000). In one study
examining patient satisfaction with Ashkenazi Jewish population-level carrier screening
for BRCA1/2 mutations, each of the 26 participants interviewed reported a need for
psychological support after receiving a positive test result (Lieberman et al., 2017). In
addition to the anxiety that many women experience after learning they carry a BRCA1/2
mutation, they also may experience feelings of stress and conflict over deciding whether
they should take preventative measures (such as major prophylactic surgery) to reduce
their cancer risk (Metcalfe et al., 2016). However, while anxiety and depression may be
the most common feelings in patients who learn they carry a BRCA1/2 mutation, it should
also be noted that some patients experience different emotions following a positive
BRCA1/2 test result, including feelings of empowerment (Crotser & Dickerson, 2010)
and even relief as a positive result can give them an explanation for why many members
of their family developed cancer.
1.7 Direct-to-consumer genetic testing for BRCA1 and BRCA2 mutations
In March 2018, 23andMe received FDA approval to report three BRCA1/2
mutations through their service (US Food and Drug Administration, 2018). 23andMe had
originally reported these BRCA1/2 gene variants as part of their previous DTC-GT
product until the FDA prohibited reporting of these results in 2013 and requested
confirmation of analytic and clinical validity. Today, anyone who purchases 23andMe’s
health and ancestry service can access their BRCA1/2 results. One major caveat of this
service is that 23andMe only reports on three out of hundreds of known mutations in
BRCA1/2. These particular mutations are typically seen in the Ashkenazi Jewish
population and are present at very low frequency in the general population (Struewing et
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al., 1995; Roa et al., 1996; Oddoux et al., 1996). This means that many people who do in
fact carry a pathogenic mutation in BRCA1 or BRCA2 will receive a negative BRCA1 and
BRCA2 result from 23andMe based on testing of the three Ashkenazi Jewish founder
mutations alone.
Physicians in recent publications have debated the risks and benefits of DTC-GT
for BRCA1/2 mutations. One physician, a surgical oncologist, says that DTC-GT for
BRCA1/2 mutations will allow more people who could benefit from this information get
tested, because it removes certain barriers to testing such as cost, location, and
availability of genetic counselors. He says, “The faster we start letting people know what
their specific problems might be, the better off our health is going to be.” On the other
hand, this particular article also cited a professor of genetics who is not in favor of DTCGT for BRCA1/2 mutations, expressing worry over possible misinterpretation of results
by consumers, or misunderstanding that results are only reported for three of the many
mutations in BRCA1 and BRCA2 (American Association for Cancer Research, 2018).
Some limited research on DTC testing for BRCA1/2 mutations exists. In a study
published in 2011, the researchers investigated how women who had family histories of
breast and/or ovarian cancer felt about direct-to-consumer advertising for BRCA1/2
testing and online availability of genetic testing. The women included in this study were
at high-risk for breast and/or ovarian cancer based on their family histories and a subset
of these women had undergone genetic testing, and a smaller subset had tested positive.
While the most women in this study were in favor of direct-to-consumer advertising for
BRCA1/2 testing because they felt it would allow women to be better informed and
proactive when it comes to their cancer risk, they were generally not in favor of genetic
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testing being available for the average person to order online (Perez et al., 2011). The
women in the high-risk clinic preferred that testing and decision-making still only be
performed with the help of a physician, with 73.8% of women agreeing that testing
should only be performed if the patient sees an expert in-person who can counsel them
about their breast cancer risk (Perez et al., 2011). This suggests women who are at high
risk for breast and ovarian cancer believe that online BRCA1/2 mutation testing could
come with more risks to consumers than benefits if a physician or genetic counselor is
not involved in the process. However, since the majority of of these women had never
received a positive test result, they may have had a limited understanding of the
implications, follow-up, and psychological challenges that come with a positive genetic
test result. Additionally, this study mainly focused on attitudes towards direct-toconsumer advertising for BRCA1/2 testing and gathered little information about how
these women felt about the genetic testing itself being offered in a direct-to-consumer
matter.
One study published in 2013 by Francke and colleagues investigated consumer
response to 23andMe’s initial phase of reporting BRCA1/2 mutation results. This study
interviewed 32 people who found out they were carriers of a BRCA1 or BRCA2 mutation
through DTC-GT. Most notably, none of these participants reported being “extremely
upset” by their result with most women and men who received a positive result reporting
that they had “neutral” feelings. Additionally, most people who received a positive result
shared their results with other relatives, and most also brought their results to a healthcare
provider for more information and confirmation. Many of the women who learned of
their mutation for the first time via 23andMe made decisions regarding their health after
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confirmation testing, including prophylactic surgeries or increased screening. Thirty of
the thirty-two mutation-positive patients interviewed also said that they would get tested
in this manner again as they felt the information was useful and potentially life-saving.
Only one participant in this study reported a negative response to learning their test
result, saying that knowing he was mutation-positive and could pass it on to his children
had a large emotional impact on him (Francke et al., 2013).
While this previous study offers evidence that DTC-GT for BRCA1/2 mutations
may not be as harmful to consumers as some have suggested, it did harbor some
significant limitations. One limitation is that the study sample was small, and half of the
participants who were interviewed regarding their positive results were men. This is
important to note, since men with a BRCA1 or BRCA2 mutation have a much lower risk
for cancer than women with a mutation and have different motivations for undergoing
testing (Liede et al., 2000). Men are more likely to cite concern for their family members
and children as reasons for pursuing genetic testing for hereditary cancer, rather than
concern for their own personal risk which is the most common reason cited by women
(Liede et al., 2000). Additionally, some research has shown that men are less likely than
women to experience anxiety or psychological distress after receiving a positive
BRCA1/2 test result, perhaps due to their lower risk for cancer than female mutation
carriers (Watson et al., 2004). Additionally, some of the women and men included in this
study had already known about a BRCA1 or BRCA2 mutation in their family or been
diagnosed with a mutation already in themselves. Finally, these patients may not
understand the major benefits or limitations of getting tested via DTC-GT in comparison

14

to the clinical setting, as most of these patients did not experience the clinical testing
process (Francke et al., 2013).
1.8 Rationale and study aims
DTC-GT is expected to grow, as is the demand for at-home genetic testing.
Currently, genetic counseling is not routinely a part of the DTC-GT process, and many
patients go through the DTC-GT process without formal genetic counseling pre-test or
post-test. This has raised concern that consumers undergoing DTC-GT for BRCA1/2
mutations may not fully understand what is being tested, the implications of positive or
negative results, or that they may experience psychological distress from receiving a test
result that they were not prepared for (Kalokairinou, Howard & Borry, 2014).
While previous studies have examined consumer perspectives of DTC-GT
(Carere et al., 2016; Ostergren et al., 2015; Roberts et al., 2017) and one study
specifically examined consumer perspectives of DTC-GT for BRCA1/2 mutations
(Francke et al., 2013), no study to our knowledge has specifically examined the
perspectives of patients who have been diagnosed with a BRCA1 or BRCA2 mutation via
the traditional clinical process on this test being offered through a DTC model. These
patients who have been through formal, traditional genetic testing are in a unique position
to offer perspectives on DTC-GT for BRCA1/2 mutations. It may be that that some
people who have been diagnosed with BRCA1/2 mutations through in-person genetic
counseling are in favor of the testing being available through DTC-GT. We know that the
information is useful, empowering, and potentially life-saving (Crotser and Dickerson,
2010), so some would argue that it should be available to everyone, regardless of whether
they are able to access a genetic counselor or have insurance. On the other hand, other
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patients may feel as though the process of going through testing and getting a positive
result was so confusing, difficult, and stressful that it should not be available for any
person to order from home without input or consent from a physician.
The goal of the present study is to investigate the attitudes of BRCA1/2 mutation
carriers regarding DTC-GT for BRCA1/2 mutations. A better understanding of patients’
attitudes and feelings about DTC-GT for BRCA1 and BRCA2 mutations will have
implications in the fields of genetics, oncology, genetic counseling, and public health. To
investigate these topics, this study has three specific aims:
Among BRCA1/2 mutation carriers identified through clinical genetic testing:
1. Evaluate attitudes towards the availability of direct-to-consumer testing for
BRCA1 and BRCA2 mutations.
•

Hypothesis: The majority of BRCA1/2 carriers surveyed will be in favor of
DTC-GT for BRCA1/2 mutations

2. Investigate which aspects of the clinical genetic testing process BRCA1/2 carriers
find most and least favorable in comparison to direct-to-consumer genetic testing,
and in which situations they may opt to choose DTC-GT over clinical testing.
•

Hypothesis: Cost and accessibility will seem favorable in DTC-GT
compared to clinical testing, while education provided and psychological
support will seem favorable in clinical genetic testing compared to DTCGT. People will be more likely to opt for DTC-GT when accessibility to
clinical testing is low or cost of clinical testing is high.

3. Determine how previous clinical genetic testing experience influences one’s
views of DTC-GT
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•

Hypothesis: People who had positive experiences with clinical genetic
testing will be less likely to support of DTC-GT for BRCA1/2 mutations.

The results of this study will help healthcare providers understand what patients
think the most favorable and unfavorable aspects of the clinical genetic testing process
are in comparison to DTC-GT, revealing the areas where improvements can be made in
the clinical process. This information will also indicate what patients perceive the
potential risks of DTC-GT for BRCA1/2 mutations might be, offering insight into how to
improve direct-access genetic testing and decrease the potential for adverse experiences
and outcomes. It will also help us understand which groups of patients who go through
DTC-GT may benefit from genetic counseling pre- or post-test.
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CHAPTER 2
BRCA1 AND BRCA2 MUTATION-POSITIVE PATIENT PERSPECTIVES ON
DIRECT-TO-CONSUMER GENETIC TESTING FOR BRCA MUTATIONS1

1

Mitchell, C., Dobek, W., Madden, S., & Carere, D.A. To be submitted to Journal of Genetic Counseling
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2.1 Abstract
Recently the FDA authorized one direct-to-consumer genetic testing (DTC-GT)
company to begin reporting certain genetic variants in the BRCA1 and BRCA2 genes.
Pathogenic variants in these genes confer lifetime risks for breast and ovarian cancer in
women as high as 87% and 62%, respectively. Historically, genetic testing for these
mutations has been offered in a clinical setting where genetic counseling is part of the
testing process. Genetic counseling is not routinely a part of DTC-GT, raising concern
that those undergoing DTC-GT for BRCA1/2 mutations may not fully understand what is
being tested, the implications of results, or that they may experience psychological
distress from receiving an unexpected result. The goal of our study was to assess how
BRCA1/2 mutation carriers who went through clinical genetic testing feel about DTC-GT
for BRCA1/2 mutations. Results indicate that most respondents are in favor of DTC-GT
for BRCA1/2 mutations being available, as it increases access to this empowering
information. However, most participants also had concerns about DTC-GT, with most
worried about false negatives and lack of counseling/support for mutation-positive
consumers. Additionally, respondents would be more likely to choose DTC-GT in a
scenario where clinical testing is difficult to access or when they had negative
perceptions of certain aspects of their own genetic testing experience. These findings
suggest that an enhanced DTC-GT model which incorporates pre- and/or post-test
counseling by a certified genetic counselor could be a viable option that would have
support from the BRCA-mutation carrier population.
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2.2 Introduction
Genetic testing has evolved rapidly since it was first utilized in the 1960s. Over
the past few decades more tests have become available and are offered at a lower price
than previously. In the mid-2000’s, direct-to-consumer genetic testing (DTC-GT) entered
the market. DTC-GT allows any consumer over the age of 18 to order certain genetic
tests for themselves without needing to involve a clinician. This is in contrast to clinical
genetic testing, where a healthcare provider typically provides some form of genetic
counseling. During this genetic counseling process, the clinician helps the patient
understand the test itself, their result and what it means for their health. They also have a
role in assessing the patient’s psychological response and addressing concerns or
questions that arise.
Information provided through DTC-GT can include ancestry, physical traits,
genetic disease risk, and carrier status (Wesselius & Zeegers, 2013). DTC-GT is
regulated by the Food and Drug Administration (FDA) and the companies can only report
on genetic information that the FDA has approved. While DTC-GT usually does not
involve the patient’s healthcare provider, some patients may choose to share their results
with their provider, and some DTC-GT companies offer post-test genetic counseling to
consumers. However, research has shown that few customers utilize post-test genetic
counseling, even when it is available (Koeller et al., 2017).
DTC-GT has generated much controversy as it has continued to grow and as the
number of tests offered has expanded. Those who support DTC-GT claim that its low
cost and easy access increase consumer autonomy and engagement in their healthcare by
helping them become more knowledgeable about their genetics. One recent study on
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DTC-GT found that after receiving results, 59% of DTC-GT customers surveyed said
that their test results would influence how they manage their health, and 65% said they
felt more in control of their health after receiving results (Roberts et al., 2017). On the
other hand, opponents of DTC-GT have many concerns, including the incorrect
comprehension or use of results by patients, or that results could cause unnecessary worry
and anxiety in patients (Annes, Giovanni, & Murray, 2010; Kalokairinou, Howard &
Borry, 2014; “What are the benefits…”, 2018). Those patients who do not have high
health literacy or a basic understanding of genetics may not understand the complexity of
genetic information that is reported via DTC-GT, or even that information they receive
from DTC-GT could have a significant impact on their lives. Previous research has
shown that consumers often report lower levels of confidence in their genetic knowledge
and understanding after they go through the process of DTC-GT than they did before
undergoing testing, indicating that patients may not fully understand the complexities of
genetic risk and inheritance prior to ordering DTC-GT (Carere et al., 2016). Additionally,
unexpected results may cause anxiety and stress, which has been documented in some
cases (Dohany et al., 2012). One study found that close to 40% of people who ordered
DTC-GT said they did not consider the possibility that they could get information they
did not want from the test (Roberts et al., 2017).
In March 2018, the debate over DTC-GT became more heated when the FDA
announced approval for one of the largest DTC-GT companies, 23andMe, to resume
reporting on certain pathogenic variants in the BRCA1 and BRCA2 genes, which are
associated with hereditary breast and ovarian cancer (US Food and Drug Administration,
2018). The company had previously reported on these variants briefly in 2013, until the
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FDA prohibited it due to lack of proper validation. With the new approval, anyone who
purchases the health and ancestry service through 23andMe for $199 can have access to
their BRCA1/2 report, which looks for three specific pathogenic variants typically found
in the Ashkenazi Jewish population.
DTC-GT for BRCA1/2 mutations has increased worry about this relatively
unsupervised form of genetic testing in many professionals. For the past 20 years,
BRCA1/2 testing has been ordered for patients by healthcare providers that take family
history and patient preferences into account while also helping patients deal with the
significant health-related and psychosocial implications of results. The lifetime risk of a
woman with a BRCA1 or BRCA2 mutation developing breast cancer is estimated to be up
to 87%, compared to 12% in the general population. A woman with a BRCA1 or BRCA2
mutation also has a lifetime ovarian cancer risk of up to 62%, compared to 1-2% in the
general population (Petrucelli, Daly & Pal, 2016). Men with BRCA1/2 mutations are at
increased risk for breast cancer and prostate cancer, and both men and women are at
increased risk for other types of cancer, including pancreatic. In women who test positive
for a BRCA1/2 mutation, national guidelines outline a number of significant changes to
medical management, including increased screening, consideration of preventative
medications, and consideration of prophylactic removal of the ovaries and/or breasts
(National Comprehensive Cancer Network, 2019). With a positive result, many patients
experience increased levels of anxiety about developing cancer and about passing on the
mutation to their children (Prospero et al., 2001).
There is a worry that consumers who learn that they carry a BRCA1/2 mutation
though DTC-GT may not fully understand what is being tested for, the implications of
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their results, or that they may experience psychological distress from receiving a test
result that they were not prepared for (Kalokairinou, Howard & Borry, 2014).
Additionally, consumers unfamiliar with genetics may not understand the limitations of
the testing. For example, BRCA1/2 testing offered through DTC-GT only looks for 3
mutations in the BRCA1 and BRCA2 genes out of thousands of known mutations, giving
many consumers that do carry a mutation a false negative result. Consumers may also not
understand the complicated implications of the result without talking to a healthcare
provider. However, some professionals are in favor of this increased access to BRCA1/2
testing, arguing it makes testing more accessible for those who may not have health
insurance, access to a genetic counselor, or experience another barrier to clinical testing.
Through DTC-GT, more people can learn that they carry a BRCA1/2 mutation and have
the opportunity to act to decrease their risk of developing cancer. A previous study has
shown that people who learn they have a BRCA1/2 mutation view the information as
useful, empowering, and potentially life-saving (Crotser and Dickerson, 2010).
Limited research has been done on DTC-GT for BRCA1/2 mutations. In one study
that examined the responses of patients to learning that they carry a BRCA1/2 mutation
through DTC-GT, it was found that no patients reported being “extremely upset” by their
result, and that 94% of patients would get tested in this manner again (Francke et al.,
2013). However, this study harbored multiple limitations, including that some
participants already knew of their mutation status before the test and that over half of the
participants were men, who have much lower BRCA1/2-associated risks for cancer
compared to women. In another study that examined the perspectives of women at high
risk for breast or ovarian cancer on DTC advertising and testing for BRCA1/2 mutations,
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it was found that many women are in favor of DTC advertising for BRCA1/2 testing but
think that the testing is best done through a healthcare provider (Perez et al., 2011).
However, most participants in this study had never tested positive for BRCA1/2 mutations
and some had never even undergone genetic testing and therefore had limited knowledge
on the genetic counseling that typically comes with a positive test result. Additionally,
this study mainly focused on direct-to-consumer advertising for BRCA1/2 testing, rather
than on the genetic testing itself being offered in a DTC-manner.
To our knowledge, no study has specifically examined the perspectives of patients
who have been diagnosed with a BRCA1 or BRCA2 mutation via the traditional clinical
process on this test being offered in a DTC model. These patients who have been through
the formal, traditional genetic testing are in a unique position to offer perspectives on
DTC-GT for BRCA1/2 mutations. They know what the traditional testing method has to
offer, and also understand the risks and benefits of learning that you carry a BRCA1/2
mutation. In this study, our objectives were (1) to assess the attitudes of BRCA1/2 carriers
who were diagnosed with clinical testing towards DTC-GT for these mutations, (2) to
investigate which aspects of DTC-GT these patients find more or less favorable
compared to clinical genetic testing and what factors would motivate consumers to
choose DTC-GT rather than clinical testing, and (3) to determine if previous genetic
testing experience influences one’s views of DTC-GT. The results of this study can help
us understand what patients think the most favorable and unfavorable aspects of the
clinical genetic testing process are in comparison to DTC-GT, revealing the areas where
improvements can be made in the clinical process. This information also indicates what
patients perceive the potential risks of DTC-GT for BRCA1/2 mutations might be,
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offering insight on how to improve direct-access genetic testing and decrease the
potential for adverse experiences and outcomes.
2.3 Materials and Methods
2.3.1 Participants
Women and men who self-reported to have a BRCA1 or BRCA2 pathogenic or
likely pathogenic variant were invited to participate in this study. Participants were
recruited via social media websites, such as Facebook support groups, and one other
online support group. Four different Facebook support groups made for BRCA1/2
mutation carriers and the national nonprofit group Facing Our Risk of Cancer
Empowered (FORCE) were contacted to recruit participants. The questionnaire was
posted two to three times in each Facebook support group during the recruitment period,
and it was posted on the FORCE Facebook page and FORCE Twitter account once.
Recruitment took place from August 2018 through January 2019. Permission was
obtained from administrators or representatives of each group prior to posting the
questionnaire. The questionnaire was posted in the groups along with a short description
of the research and study requirements. Participants were instructed that they could skip
any question that made them uncomfortable or that they did not wish to answer. Informed
consent was obtained from each participant prior to starting the questionnaire. The
questionnaire contained three eligibility questions at the beginning to ensure only
responses from the desired population would be obtained: 1) they carried a BRCA1/2
mutation; 2) they were the first person in their family found to carry this mutation; and 3)
their genetic testing was ordered by a healthcare provider, such as an oncologist, surgeon,
OB/GYN, family physician, genetic counselor, or nurse. Participants were also required
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to be over the age of 18 and English-speaking (due to a lack of translated survey
materials). To be included in data analysis, participants must have completed the majority
of questions through the end of the questionnaire. While study recruitment was not
gender-specific, males were ultimately excluded from data analysis, since there were so
few of them (see Results below). Participants were informed that they had the option to
be included in a drawing for a $10 Amazon.com gift card upon completion of the
questionnaire if they desired. They were also informed that their responses would be
anonymous. The winner of the drawing was chosen in February 2019.
2.3.2 Instrumentation
An original questionnaire utilizing skip logic was developed through
SurveyMonkey.com (Appendix A). The survey consisted of seven sections: Consent,
Eligibility, Demographic Information, Prior Genetic Testing Experience, Direct-toConsumer Testing Attitudes, Scenarios, and Final Thoughts/Concerns. Section 1
(Consent) included information about the study and the raffle. Consent was assumed
upon clicking “OK” at the bottom of the consent page. Those who did not provide
consent were not permitted to complete the study. Section 2 (Eligibility) included 3
questions to determine whether participants met eligibility requirements related to genetic
testing history (described above). Participants who answered “No” to any of the
eligibility questions were routed out of the study. Section 3 (Demographic Information)
included nine multiple choice questions to gather information about gender, age, race,
country of residence, level of education, household income, and health insurance. Section
4 (Prior Genetic Testing Experience) included Likert scale, select all that apply, and
multiple-choice questions to assess how participants viewed their clinical genetic testing
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experience. Questions included who ordered the testing, why they were considered for
testing, what type of testing was ordered, to what extent their testing was covered by
insurance, their wait time for results, and their satisfaction with different aspects of the
genetic testing process. For the question asking who ordered the genetic testing, most
respondents who selected “other” specified “surgeon”, so an additional category for
surgeon was created for data analysis. We assessed feelings about their positive result as
well as what actions they took after learning their result. We then provided a description
of DTC-GT in the questionnaire before asking patients questions pertaining to the topic
in Section 5 (DTC Testing Attitudes). This description of DTC-GT included the typical
ordering process, cost, how results are delivered and what information results might
include. Additionally, information was included about the recent FDA approval of testing
for BRCA1/2 mutations in a DTC manner. Section 5 (DTC Testing Attitudes) consisted of
multiple-choice and Likert scale questions to gather information about how participants
perceived DTC-GT for BRCA1/2 mutations, including its benefits and limitations. We
also surveyed each participant’s familiarity with DTC-GT and whether they had
previously undergone any sort of DTC-GT themselves. Section 6 (Scenarios) included
multiple Likert scale questions relating to different scenarios (for example, if they had the
option to pursue clinical testing for $300 or DTC-GT for $99), and whether the
participant would choose DTC-GT or clinical genetic testing in each scenario, with the
option to leave additional open comments for each question. Section 7 (Final
Thoughts/Concerns) included two multiple-choice questions with the option to include
comments. These final questions were meant to obtain participants’ final thoughts on the
use of DTC-GT for BRCA1/2 mutations and whether they had any concerns. Overall, the
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questionnaire contained 30 questions (excluding eligibility questions) and was designed
to take 10-15 minutes to complete. The questionnaire in its entirety is included in
Appendix A.
2.3.3 Statistical analysis
Quantitative questions were analyzed using descriptive statistics. For
demographic questions and questions pertaining to previous genetic testing experience,
data produced was categorical. Frequencies and percentages were calculated for all
quantitative questions to summarize participants’ responses. For Likert scale (Likert
scale: 1-5) questions related to patient satisfaction, favorability of DTC-GT compared to
clinical testing, hypothetical scenarios, and support/concerns about DTC-GT, means were
calculated in order to obtain average overall scores related to these topics. To test our
hypothesis that a positive previous genetic testing experience would influence whether
participants were in favor of DTC-GT, a Pearson’s product-moment correlation was used
to determine whether satisfaction with any aspect of previous genetic testing experience
(survey items 15-17) was correlated with whether participants overall supported DTCGT, had concerns about DTC-GT, or whether they would have chosen DTC-GT or
clinical genetic testing for themselves if given the opportunity to choose again.
Additionally, as an exploratory exercise, a Pearson’s product-moment correlation was
used to determine whether any demographic factor (survey items 1-9) or favorability of
DTC-GT compared to clinical genetic testing (survey item 22) was correlated with
whether participants overall supported DTC-GT or had concerns about it. All correlations
were univariate and unadjusted for other variables. SPSS software was utilized for data
analysis and the alpha level for statistical testing was set at 0.05. For open response
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comments, thematic analysis was performed to identify themes across responses for each
question.
2.4 Results
2.4.1 Exclusion and Demographic Information
A total of 288 individuals began and consented to the survey. Of these, 188
participants completed the three eligibility questions and qualified for inclusion in the
study. On average, participants spent about 10 minutes completing the questionnaire. Of
the 188 participants who initiated the survey, 33 did not complete it and were excluded
from analysis. Due to the small number of male participants (3 of 188), males were
excluded from the final analytic sample. Demographic characteristics of the 152
participants included in the analysis are summarized in Table 2.1. Most participants were
Caucasian (94.1%) and had at least a college degree (69.7%). The ages of participants
ranged from 26 to 65 with an average age of 47.26 years. Most (77.6%) participants
reported having children, having health insurance (96.1%), and an annual household
income of ≥$100,000 (54%). A minority (6.6%) resided outside of the US.
2.4.2 Previous Genetic Testing Experience
On average, participants tested positive for a BRCA1/2 mutation at an age of 43.7
years (range = 21 to 62). Most patients had their genetic counseling performed by either
an oncologist (31.6%), a genetic counselor (36.8%), or an OB/GYN (25%) (Table 2.2).
Participants were most often referred for genetic testing due to either a personal history of
cancer (47%) or a family history of cancer (48.4%). A minority of participants sought
genetic testing on their own. The majority (57.9%) of participants stated that they
underwent panel testing compared to 31.6% who underwent testing for
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Table 2.1 Demographic characteristics of survey participants
Characteristics
Frequency Percent
Race (n=152 )
White or Caucasian
143
94.1*
Hispanic or Latino
10
6.6
Asian or Asian-American
1
0.7
American Indian or Alaska Native
2
1.3
Another race
1
0.7
Unknown/do not wish to specify
2
1.4
Country of residency (n=152)
United States
142
93.4
Other
10
6.6
Highest level of education (n=152)
High school
8
5.3
Some college
37
24.3
College degree
61
40.1
Some graduate school
2
1.3
Graduate/Doctoral/Professional degree
44
28.9
Annual household income (n=152)
Under $40,000
8
5.3
Between $40,000 and $99,999
62
40.8
Between $100,000 and $199,999
52
34.2
$200,000 or greater
15
9.9
Prefer not to answer
15
9.9
Have children (n=152)
Yes
118
77.6
No
34
22.4
Health insurance coverage (n=152)
Yes
146
96.1
No
6
3.9
Age in years (n=152)
Mean ± standard deviation (range)
47.26 ± 9.7 (26-65)
*Percentages add up to >100% because participants were told to “Select all that apply”
BRCA1/2 alone. The majority of participants also had their testing fully covered by
insurance (70.5%) and waited between 1 and 4 weeks for their results (69.8%).
When asked about overall satisfaction with their genetic testing experience (Table
2.2), the vast majority of participants were either somewhat satisfied or very satisfied
(82.2% of participants). When asked to rate different aspects of their genetic testing
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Table 2.2 Previous genetic testing experience
Aspect of experience
Frequency Percent
Who ordered the testing (n=152)
Oncologist
48
31.6*
Genetic counselor
56
36.8
Obstetrician or gynecologist
38
25
Family practitioner
12
7.9
Surgeon
14
9.2
Advanced practice nurse in genetics
1
0.7
Other
6
3.9
How were you referred for genetic testing? (n=151)
Referred by doctor or other healthcare provider after personal
history of cancer
68
45
Referred by doctor or other healthcare provider due to family
history of cancer
56
37.1
Referred by doctor or other healthcare provider for another
reason
5
3.3
Sought testing on my own due to personal history of cancer
3
2
Sought testing on my own due to family history of cancer
17
11.3
Sought testing on my own for another reason
2
1.3
Type of genetic testing ordered (n=152)
BRCA1 and BRCA2 genes only
48
31.6
Panel testing
88
57.9
Unsure/don't remember
16
10.5
How much of testing was covered by insurance (n=149)
Fully covered
105
70.5
Partially covered (had to pay a co-pay)
35
23.5
Not covered at all (paid out-of-pocket)
9
6
Wait time for results (n=152)
<1 week
5
3.3
1-2 weeks
39
25.7
2-4 weeks
67
44.1
4-8 weeks
33
21.7
>8 weeks
8
5.3
Satisfaction with genetic testing experience (n=152)
Very satisfied
75
49.3
Satisfied
50
32.9
Neither satisfied or dissatisfied
18
11.8
Dissatisfied
7
4.6
Very dissatisfied
2
1.3
Feelings after results (Scale of 1-5 with 1 being not at all and 5 being extremely)
Surprised (mean) (n=150)
3.07
Upset (mean) (n=148)
3.64
Relieved (mean) (n=145)
1.86
*Percentages add up to >100% because participants were told to “Select all that apply”
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experience on a scale of 1 (very dissatisfied) to 5 (very satisfied), people rated the ease of
accessing a clinic and information provided on BRCA1/2 genes and cancer highest, with
means of 4.38 and 4.15, respectively (Table 2.3). People reported being least satisfied
with the psychological support provided and the information provided on
management/treatment for positive results, with means of 3.16 and 3.84, respectively.
We asked participants about their feelings and actions taken after receiving their
positive results. When asked to rate how surprised, upset, and relieved they were on a
scale of 1 (not at all) to 5 (extremely), participants were on average moderately surprised
(mean= 3.07), moderately upset (mean= 3.64), and were not likely to feel relieved
(mean= 1.87).
Table 2.3 Satisfaction with previous genetic testing
1
very
Aspect of experience negative
Time to get an
4
appointment
(2.7%)
(n=150)
Ease of accessing a
0
clinic (n=150)
Cost of testing
10
(n=147)
(6.8%)
Risk assessment
6
(n=149)
(4.0%)
Information/educati
4
on on BRCA1/2
(2.7%)
(n=150)
Psychological
22
support (n=147)
(15.0%)
Information on
5
management
(3.4%)
(n=149)
Risk estimation for
6
other family
(4.0%)
members (n=150)
SD= standard deviation

4

5
very
positive

Mean
Score
± SD

29
(19.3%)

34
(22.7%)

75
(50.0%)

4.1 ±
1.1

2
(1.3%)
9
(6.1%)
4
(2.7%)

30
(20.0%)
34
(23.1%)
34
(22.8%)

27
(18.0%)
21
(14.3%)
25
(16.8%)

91
(60.7%)
73
(49.7%)
80
(53.7%)

4.4 ±
0.8
3.8 ±
1.3
4.1 ±
1.1

13
(8.7%)

19
(12.7%)

35
(23.3%)

79
(52.7%)

4.1 ±
1.1

25
(17.0%)

40
(27.2%)

27
(18.4%)

33
(22.4%)

3.2 ±
1.4

20
(13.4%)

29
(19.5%)

35
(23.5%)

60
(40.3%)

3.8 ±
1.2

12
(8.0%)

36
(24.0%)

41
(27.3%)

55
(36.7%)

3.8 ±
1.1

2

3
neutral

8
(5.3%)
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After receiving results, the most common actions taken were prophylactic surgery
(75.0%) and communication of results to other family members (71.1%).
2.4.3 DTC-GT Familiarity and Attitudes
Prior to completing our study, the majority of participants either knew what DTCGT was (57.6%) or had familiarity with the term but weren’t sure what it meant (15.9%).
About one quarter of participants (23.2%) had undergone DTC-GT before, such as
23andMe or Ancestry DNA. If participants had been given the option between DTC-GT
and clinical genetic testing at the time they were undergoing their testing, most
participants indicated that they would have definitely or probably chosen clinical testing
(80.3%), and 12.0% were not sure which they have chosen. The remaining 6.7% said
they would have probably or definitely chosen DTC-GT (Figure 2.1).
2.4.4 DTC Testing vs Clinical Testing
We asked participants to compare different aspects of DTC-GT to clinical genetic
testing. The results are displayed in Table 2.4. Participants thought the accessibility of
DTC-GT was increased compared to clinical genetic testing. However, on average
participants rated information/education provided in DTC-GT and psychosocial support
provided in DTC-GT lower that what is provided in clinical testing.
2.4.5 Scenarios
We presented participants with different scenarios related to pursuing BRCA1/2
testing. We asked participants to indicate whether they would have chosen DTC-GT or
clinical genetic testing in each scenario on a scale of 1 (definitely clinical) to 5 (definitely
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DTC). The results are presented in Figure 2.1. Participants more frequently preferred
DTC-GT when the cost was significantly cheaper ($99 DTC vs $250-400 clinical), with
Table 2.4 DTC-GT compared to clinical testing
1
very
unfavorable
compared
to clinical
33
(23.1%)
8
(5.7%)

Cost of DTC
(n=143)
Accessibility of
DTC (n=141)
DTC
9
turnaround
(6.6%)
time (n=137)
DTC education/
information
71
provided
(50.7%)
(n=140)
Psychosocial
81
support in DTC
(58.3%)
(n=139)
SD= standard deviation

2

3
same as
clinical

4

17
(11.9%)
12
(8.5%)

26
(18.2%)
33
(23.4%)

28
(19.6%)
41
(29.1%)

5
very
favorable
compared
to clinical
39
(27.3%)
47
(33.3%)

19
(13.9%)

89
(65.0%)

12
(8.8%)

8
(5.8%)

2.9 ±
0.9

40
(28.6%)

24
(17.1%)

4 (2.9%)

1
(0.7%)

1.7 ±
0.9

35
(25.2%)

19
(13.7%)

3 (2.2%)

1
(0.7%)

1.6 ±
0.9

Mean
Score
± SD

3.2 ±
1.5
3.8 ±
1.2

52% saying they would definitely or probably prefer DTC in this scenario. However,
86.7% of participants definitely or probably preferred clinical testing if the mutation
carrier detection rates for DTC-GT and clinical testing were 15% and 95%, respectively.
They also more frequently said they would recommend clinical testing for their friend,
even if the friend may not meet clinical testing criteria, with 87.4% of participants saying
they would definitely or probably recommend clinical testing. For the other scenarios
presented, responses were relatively evenly distributed between preferring DTC-GT and
clinical testing. When asked if their children desired to pursue DTC-GT rather than
clinical testing to see if they carried the same mutation that they had, 66.9% participants
indicated that they would probably or definitely support their child’s decision.
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Definitey clinical
160

n=151

Probably clinical

Not sure

n=150

n=151

Probably DTC
n=150

Definitely DTC
n=151

140
120
100
80
60
40
20
0
2 month wait for $250-400 for clinical 2 hour drive for DTC detects 15% of Recommend your
clinical vs DTC
vs $99 for DTC clinical vs DTC from mutations vs clinical friend get clinical
immediately
home
detects 95% of
testing where she
mutations
may not meet
criteria or
recommend she get
DTC that detects
15% of carriers

Figure 2.1 BRCA1/2 carrier preference between DTC-GT and clinical genetic testing
in different scenarios
2.4.6 Overall support and concerns
Finally, we asked participants whether they were overall in support of DTC-GT
for BRCA1/2 mutations being available to the general public. Results are displayed in
Figure 2.2. The majority of respondents indicated that they either somewhat or strongly
supported DTC-GT availability for BRCA1/2 testing (52%), while 25.7% were undecided
and 22.3% were somewhat or strongly against it. When asked whether they had concerns
about DTC-GT being available, 69.7% of participants indicated that they were either
“moderately” or “extremely” concerned about DTC-GT for BRCA1/2 mutations without
involvement from a healthcare provider while 17.1% of participants indicated that they
were not concerned or that they were undecided.

35

A

Overall, do you support DTC genetic testing for
mutations in the
BRCA1 and BRCA2 genes being available to the general
public? (n=152)

6%
26%

Strongly against

16%

Somewhat against
Neutral/not sure

26%

B

Somewhat support

26%

Strongly support

Are you concerned about people ordering DTC testing
for BRCA1
and BRCA2 mutations without involvement from any
healthcare provider? (n=152)
3%

14%
31%

Not concerned
13%

Slightly conerned
Moderately concerned
Extremely concerned
Not sure/undecided

39%

Figure 2.2 BRCA1/2 carrier support (A) and concerns about (B) DTC-GT for
BRCA1/2 mutations
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2.4.7 Thematic analysis
Within the questionnaire, we asked participants to elaborate on their responses to
the questions about whether they overall support DTC-GT availability for BRCA1/2
mutation testing and about whether they had concerns about DTC-GT for BRCA1/2
mutations. Sixty-eight participants elaborated on their support/lack of support for DTCGT and 66 participants elaborated on concerns they had. For both questions, themes were
broken down into concerns regarding DTC-GT for BRCA1/2 mutations and reasons for
supporting DTC-GT for BRCA1/2 mutations.
2.4.7.1 Concerns regarding DTC-GT for BRCA1/2 mutations
For both questions, accuracy and false negatives associated with the testing was a
major concern with DTC-GT. When asked whether they support DTC-GT, 31 of the
respondents (45.6%) cited accuracy and/or false negative concerns as a reason they may
not support it. When asked specifically about their concerns regarding DTC-GT for
BRCA1/2 mutations, 21 respondents (31.8%) cited accuracy/false negative concerns.
“I believe the results are not accurate, misleading and dangerous”
“Too many false negatives, which gives a sense of security that is false
and is risky”
Another theme that emerged was that participants were concerned about lack of
healthcare provider guidance on how to handle a positive test result with DTC-GT. When
asked to describe what their concerns were, 31 respondents (47%) said they were
concerned about lack of involvement from a healthcare professional, either for
psychosocial support or for answering questions about navigating next steps. Of these 31
respondents, 26 specifically cited that people may not understand clinical management
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without a healthcare provider, and 12 cited a provider should be involved for
psychosocial support (7 participants cited both concerns).
“Counseling, explanations, questions answered in person and
immediately as I heard result was so helpful. I would not have wanted to
be alone with no other info”
“Finding out you have this mutation has created nothing but anxiety and
depression. To tell someone they have this mutation or them finding out
can be a shock and without some form of support can lead to severe
depression”
2.4.7.2 Reasons for supporting DTC-GT for BRCA1/2 mutations
Two main themes emerged for reasons to support DTC-GT for BRCA1/2
mutations: increased accessibility and empowerment. Of the 68 respondents who
elaborated on why they did or did not support DTC-GT for BRCA1/2 mutations, 24
(35.3%) said they supported it because it increases accessibility to BRCA1/2 testing, with
7 respondents (10.3%) specifically mentioning it would be a good option for those who
cannot afford clinical testing.
“I believe everyone should be able to know what health mutations/risks exist for
them. Saying they have to get it from a clinic will prevent many people from
seeking the information”
Six participants commented that more people being able to learn their genetic
status is a benefit that empowers patients to take action.
“It's important to get information in the hands of patients so they can take control
of their health”
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2.4.8 Correlations
No significant correlations were observed between satisfaction with any aspect of
previous genetic testing experience and whether participants were overall in support or
concerned about DTC-GT for BRCA1/2 mutations. Multiple correlations were found
between aspects of previous genetic testing experience and whether participants would
have chosen DTC-GT or clinical testing for themselves (assuming accuracy was the same
for each test). For previous genetic testing experience, time it took to get an appointment,
ease of accessing a clinic, cost of testing, information provided on BRCA1/2 genes and
cancer, information provided on management for positive results, and risk estimation for
family members were all significantly correlated with whether participants would have
preferred DTC-GT or clinical testing for themselves. People who rated these aspects of
their genetic testing more positively were more likely to have chosen clinical testing for
themselves while those who rated these aspects of their own experience negatively were
more likely to have chosen DTC-GT for themselves, with ease of accessing a clinic and
risk assessment having the strongest significant correlations (p=0.001), followed by time
to get an appointment (p=0.012) and cost of testing (p=0.013). Psychosocial support was
the only factor related to previous genetic testing experience that was not significantly
correlated with which form of testing participants would have chosen for themselves
(p=0.078).
How participants viewed psychosocial support with DTC-GT was correlated with
whether they supported DTC-GT for BRCA1/2 mutations and with whether they had
concerns with DTC-GT for BRCA1/2 mutations. A lower rating of psychosocial support
provided with DTC-GT was correlated with less support of its availability (p=<0.001)
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and more concerns (p= 0.007). Additionally, there was a positive correlation between
participant age and level of concern about DTC-GT for BRCA1/2 mutations (p=0.04).
2.5 Discussion
This study aimed to elucidate the attitudes of BRCA1/2 mutation carriers toward
DTC-GT of the BRCA1 and BRCA2 genes. In surveying BRCA1/2 carriers who were
diagnosed via clinical genetic testing, we found that most participants supported the
general availability of DTC-GT for BRCA1/2 mutations, in particular because it improves
accessibility to this important information. However, most participants also had concerns
related to the accuracy of DTG-GT and the availability of clinical and psychological
support for mutation-positive patients.
We anticipated that most BRCA1/2 carriers would support DTC-GT for BRCA1/2
mutations, and not surprisingly, the most commonly cited reason in support of DTC-GT
was improved access to testing. Specifically, multiple participants noted that DTC-GT
might be a good option for women who desired testing but experienced barriers (such as
financial difficulties) to accessing clinical genetic testing. In general, participants rated
the accessibility of DTC-GT superior to the accessibility of clinical testing, and those
participants who rated accessibility-related aspects (e.g., ease of accessing a clinic or cost
of testing) of their previous genetic testing experience more negatively were more likely
to prefer DTC-GT for themselves if given the choice again. This aligns with previous
research that has shown that consumers of DTC-GT strongly support the increased
accessibility of genetic testing that DTC-GT offers (Gollust et al., 2017). Even genetics
professionals agree that DTC-GT could be a viable option for patients who want genetic
testing but have limited accessibility to clinical testing. In one study, 90% of genetic
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counselors surveyed said they would definitely or possibly consider referring a patient to
DTC-GT if that patient had limited access clinical testing due to where they live, and
over 70% of genetic counselors said they would consider referring patients to a DTC-GT
company if they had concerns over privacy or genetic discrimination (Hock et al., 2011).
Additionally, previous research has shown that most women who are at high risk of
developing breast and/or ovarian cancer are in favor of direct-to-consumer advertising for
BRCA1/2 genetic testing, asserting that direct-to-consumer advertising may be a good
way of helping women be informed about potential genetic risks for breast and ovarian
cancer and allowing them to take action by speaking to their healthcare provider (Perez et
al., 2011). Multiple participants in our study also highlighted DTC-GT could lead to
increased patient empowerment.
Historically, surveys have suggested that people affected with genetic conditions
or at-risk for genetic conditions are generally not in favor of DTC-GT. In a 2011 study,
only 20% of women who were at high risk for breast and/or ovarian cancer surveyed said
that they thought online access to genetic testing for BRCA1/2 gene mutations was a good
idea (Perez et al., 2011). A survey of cystic fibrosis patients and parents of patients found
that they were generally skeptical of DTC-GT for cystic fibrosis carrier status and the
majority believed that a healthcare provider should be involved (Janssens et al., 2015).
Our finding that the majority of BRCA1/2 carriers surveyed were in favor of DTC-GT for
BRCA1/2 mutations differs from these previous findings. One reason may be that over the
past few years, our society has become increasingly more accepting and trusting of
technology and internet-based companies (Rainie & Anderson, 2017). Additionally,
many women supported DTC-GT in this study because it was an option for people who
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had limited accessibility to clinical testing. When asked what they would prefer for
themselves, most women in our study indicated they still would prefer clinical testing
over DTC-GT. Overall, it seems that while these women generally see clinical genetic
testing for BRCA1/2 mutations as superior to DTC-GT as has been found in previous
studies, they believe DTC-GT should be available for those who may not have easy
access to clinical testing.
While participants were generally not opposed to the availability of DTC-GT for
BRCA1/2 mutations, they also indicated that they had concerns with DTC-GT for these
mutations. The majority also indicated that they still would have pursued clinical testing
over DTC-GT if given a choice between the two options. The most frequent concern was
accuracy of DTC-GT and false negatives. Currently, the DTC-GT for BRCA1/2 being
offered via 23andMe only reports on three total mutations out of thousands of known
mutations in these genes. This means that the vast majority of true BRCA1/2 mutation
carriers tested through 23andMe will receive a negative BRCA1/2 report. While we did
not explicitly tell participants this information within our questionnaire, many cited this
limitation of the test in the free response portion of the questionnaire. When presented
with a scenario in our survey where DTC-GT detects 15% of BRCA1/2 mutations while
clinical testing detects 95%, only 4 out of 150 respondents indicated they would likely
choose DTC-GT over clinical testing. Taken together with the responses to the openended questions, this indicates that patients would strongly prefer the test that has a
higher detection rate if given the opportunity to choose, and that participants are worried
about false reassurance in those patients who do not understand the limitations of a
negative result with DTC-GT.
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Participants were also concerned about limited information and support for those
who have positive results. Similar concerns have been raised by both consumers and
healthcare professionals in the past. There have been reports of people learning that they
were BRCA1/2 mutation carriers via DTC-GT and having a significant negative reaction,
including a case report where a woman experienced psychological distress and difficulty
comprehending her positive result (Dohany et al., 2012) and a participant in another
study stating that learning he carried a BRCA mutation via DTC-GT caused him
emotional distress (Francke et al., 2013). Additionally, multiple respondents in our study
commented that they desired psychological support and needed a clinician to answer
questions when learning their own result. However, the limited research done on this
topic has shown that most people who learned of their BRCA1/2 mutation via DTC-GT
did not report having extreme negative reactions to learning their result, and the majority
also brought their results to discuss and review with a healthcare provider (Francke et al.,
2013), suggesting that while risks of learning about BRCA1/2 carrier status via DTC-GT
may be present, they may not be as prevalent as some believe.
Increased accessibility to genetic testing via DTC-GT may be particularly relevant
when testing for BRCA1/2 mutations. Often, clinical genetic testing for BRCA1/2 will not
be covered by insurance unless the patient meets specific criteria set by insurers, even
when the clinician feels they could benefit from testing. In other cases, clinicians may not
recognize patients who may benefit from testing due to small family size or limited
family history information. Indeed, previous research has shown that as many as half of
women found to be BRCA1/2 mutation carriers post-cancer-diagnosis did not meet testing
criteria prior to their own diagnosis (Weitzel et al., 2007). Therefore, the availability of
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DTC-GT for BRCA1/2 mutations has the potential to identify carriers that may have been
missed in a clinical setting due to lack of insurance coverage or if they have limited
personal and family histories of cancer.
Due to the small sample size of this study, and the inability to adjust for
confounding via multivariable analyses, we were limited to exploratory analyses of the
correlations between variables. Nonetheless, our data suggest some future avenues of
investigation that may be worthwhile to pursue. For example, we found no significant
correlations between any aspect of participants’ previous genetic testing experience and
whether they were in support of DTC-GT; there were significant correlations between
how women rated psychological support with DTC-GT and whether they overall
supported it and had concerns about it. Those who rated psychological support lower in
DTC-GT were less likely to support it and had more concerns. It is well-established that
psychological support is an important part of the genetic counseling process of women
who receive a positive BRCA1/2 result (i.e. Lieberman et al., 2017), so it is not surprising
that women who have experienced the psychological challenges that come with a positive
result may be less supportive of a testing model that offers less psychological support.
Age was also positively correlated with level of concern about DTC-GT for BRCA1/2
mutations. This may be due to older individuals having more negative attitudes towards
new technologies (Hauk, Hüffmeier & Krumm, 2018). These associations warrant further
investigation.
2.5.1 Limitations
Although our survey was open to both men and women, only 3 men qualified for
our study and began the questionnaire compared to 181 women. There are a few possible
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explanations for this significant discrepancy in the sex of the participants. One reason is
that women are more likely to undergo genetic testing BRCA1/2 mutations and therefore
be identified as carriers (Daly, 2009). Additionally, research shows that women tend to be
more engaged in their healthcare (i.e. Etingen et al., 2018) and are more likely to
participate in support groups than men (Krizek et al., 1999; Lieberman, 2008) which is
where most of our participants were recruited from. A future survey of male carriers
would be needed to determine if men hold similar attitudes towards DTC-GT for
BRCA1/2 mutations.
While our study was open to people of all ethnic backgrounds, we did not have
any participants in our study who identify as African-American or black. There are a few
potential reasons for this. One reason is that the results of genetic testing vary based on
ethnicity. For example, about 5-6% of people of Caucasian ancestry get a variant of
unknown significance as a result, while that number can be as high as 21% in AfricanAmericans (Ready et al., 2011). Additionally, it has been well-established that AfricanAmericans tend to have less access to specialty healthcare providers compared to the
Caucasian population and are less likely to pursue genetic testing than the Caucasian
population (Forman & Hall, 2009). Future recruitment from African-American and other
minority-focused support groups or patient communities could help to reach these groups.
The current dataset does not permit us to investigate similarities and differences in
attitudes towards DTC-GT across ethnic groups.
Participants for this study were recruited from support groups made specifically
for people who have a strong genetic predisposition for breast and ovarian cancer. This is
only a small proportion of BRCA1/2 mutation carriers and, as mentioned previously, is
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not accurately representative as the entire BRCA1/2 mutation carrier population.
Therefore, our results may not be generalizable to the BRCA1/2 mutation carrier
population as a whole, especially males and people of ethnicities other than Caucasian.
2.5.2 Future Research
To make the results of this research more generalizable, further research could be
conducted with a more diverse group of participants, including additional participants of
different ethnic backgrounds, socio-economic status, and males. Recruiting mutationpositive participants outside of support groups, such as directly through a genetics clinic
or high-risk breast cancer clinic, would provide a less-biased sample of participants.
Additionally, further research could be done gathering the thoughts and perspectives of
people who went through genetic counseling and genetic testing for BRCA1/2 mutations
and tested negative, as undergoing the clinical genetic testing process and receiving a
negative result entails a set of psychosocial and genetic counseling challenges that are
different from those patients who receive a positive result. Understanding the limitations
of testing and residual risk that accompany a negative result are an important part of the
clinical genetic testing process and it would be interesting to see how this population of
patients feel about DTC-GT for BRCA1/2 mutations, especially since most patients who
do undergo genetic testing for hereditary cancer predisposition syndromes receive a
negative result (LaDuca et al., 2014; Couch et al., 2017).
2.5.3 Conclusions & Practice Implications
This study is the first to our knowledge with the primary goal of investigating the
perspectives of BRCA1/2 mutation carriers on DTC-GT for BRCA1/2 mutations. Overall,
our study shows that even among those patients who would be most aware of the
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potential utility of clinical genetic testing (i.e., those who received a diagnosis through
testing), there was support for the availability of DTC-GT. Because participants’
concerns were largely limited to the those surrounding accuracy and availability of
adequate counselling and follow-up support, it may be that an enhanced DTC-GT model
which incorporates pre- and/or post-test counseling by a certified genetic counselor could
be a viable option that would have support from the BRCA-mutation carrier population.
Participants believed that the accessibility of DTC-GT is beneficial to those who may not
have access to genetic testing otherwise. In fact, women surveyed were more likely to
indicate they would have chosen DTC-GT for themselves if cost of clinical testing was
significantly higher, the drive to a clinic was far, or there was a long wait for an
appointment. Further, negative experiences with cost and clinic accessibility with their
own clinical testing were correlated with preference for DTC-GT if they were to get
tested again. These findings suggest that potential BRCA1/2 carriers may be willing to
sacrifice the genetic counseling offered through clinical testing in favor of easy
accessibility, highlighting the need to focus on expanding accessibility of clinical genetic
testing to a broader population.
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APPENDIX A
WEB-BASED QUESTIONNAIRE
Hello,
Thank you for your interest in our study. You are being asked to participate in our study
because you are a carrier of a BRCA1 or BRCA2 mutation that was identified through
clinical genetic testing. Your participation in this study is voluntary and you can choose
to leave the study at any time. You can choose to skip (not answer) individual questions
in the survey. Your answers will be anonymous (your responses cannot be linked to your
personal identity) and confidential (your responses will be stored securely, and only
accessible to members of the research team conducting the study). By completing this
survey, you are consenting to its use in this study and any future research, presentations,
or publications. However, you may withdraw your consent at any time by contacting the
individuals listed below. The risks of participating in this study are minimal: you may
experience negative emotions when recalling your genetic testing experience. There is no
direct personal benefit to participating in this study; however, your input may contribute
to improved understanding of patient preferences for genetic counseling and direct-toconsumer access to genetic testing.
The online questionnaire should take about 10-15 minutes to complete. Each participant
who completes the survey has the option to be entered in a drawing to win a $10 Amazon
gift card. One drawing will take place for the gift card at the completion of data
collection. If you wish to enter the drawing, a link will be given at the end of the
questionnaire where you can provide your email to enter the drawing without connecting
your email address to your previous answers. The winner of the drawing will be notified
via email in February 2019.
If you have any questions, please do not hesitate to contact me by email at
caitlyn.mitchell@uscmed.sc.edu or my advisor, Alexis Carere, ScD, CGC at
alexis.carere@lhsc.on.ca. Additionally, please contact myself or my advisor via email if
you wish to receive the results of the survey once it is complete.
Sincerely,
Caitlyn Mitchell, MS
Genetic Counseling Student
University of South Carolina
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Page 1: Eligibility
1. Have you tested positive for a mutation in BRCA1 or BRCA2?
a. Yes [continue to next page]
b. No [exit survey to “thank you” page]
Page 2: Eligibility
2. Were you the first person in your family found to have this mutation?
a. Yes [continue to next page]
b. No [exit survey to “thank you” page]
Page 3: Eligibility
3. Did you receive genetic testing through a cancer clinic or genetics clinic,
where a genetic counselor, oncologist, or other physician or health care
provider ordered the test? (Note: if you learned of your mutation via a directto-consumer testing company, such as 23andMe or Color Genomics, please
answer “No”)
a. Yes [continue to next section]
b. No [exit survey to “thank you” page]
Page 4: Demographic Information
1. What is your gender?
i) Male
ii) Female
iii) Prefer not to answer
2. What is your age? [blank box for age]
3. How old were you when you tested positive for a BRCA1 or BRCA2 mutation?
(approximate if unsure) [blank box for age]
4. What is your race? (Select all that apply)
i) Alaska Native
ii) American Indian
iii) Asian
iv) African American
v) Caucasian
vi) Hispanic
vii) Native American
viii) Native Hawaiian/Pacific Islander
ix) Unknown
x) Other
xi) Do not wish to specify
5. Do you reside in the United States?
i) Yes
ii) No
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6. What is your highest level of education
i) High school
ii) Some college education
iii) College degree
iv) Some graduate school
v) Doctoral/Professional degree
7. What is your annual household income?
i) <$40,000
ii) $40,000-$99,999
iii) $100,000- $199,999
iv) >$200,000
v) Prefer not to say
8. Do you have children?
i) Yes
ii) No
9. Do you have health insurance?
i) Yes
ii) No
Page 5: Genetic testing experience
10. Who ordered your cancer genetic testing?
a. Oncologist
b. Genetic counselor
c. Obstetrician or gynecologist
d. Family practitioner (family doctor or family nurse practitioner)
e. Advanced practice nurse in genetics (APNG)
f. Other (please specify): _______________________
11. How were you referred for genetic testing?
a. Referred by doctor or other healthcare provider after personal history
of cancer
b. Referred by doctor or other healthcare provider due to family history
of cancer
c. Referred by doctor for another reason
d. Sought genetic counseling on my own due to personal history of
cancer
e. Sought genetic counseling on my own due to family history of cancer
f. Sought genetic counseling on my own for another reason
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12. What type of testing was ordered for you?
a. BRCA1 and BRCA2 genes only
b. A panel (large number) of genes, including more than BRCA1 and
BRCA2
c. I don’t remember
13. To what extent was your testing covered by insurance?
a. Fully covered
b. Partially covered (i.e. I had to pay a co-pay)
c. Not covered at all, paid out-of-pocket
14. How long did you wait for results?
a. Less than 1 week
b. Between 1 and 2 weeks
c. Between 2 and 4 weeks
d. Between 4 and 8 weeks
e. Over 8 weeks
Page 6: Genetic testing information (continued)
15. Overall, how satisfied were you with your genetic testing experience?
1- Very unsatisfied
2- Somewhat unsatisfied
3- Neutral
4- Somewhat satisfied
5- Very satisfied
16. Please rate the following aspects of your genetic counseling or genetic testing
experience on a scale of 1 (Very negative) to 5 (Very positive)
1
Very
Negative
Time to get an appointment
Ease of accessing a clinic
Cost of testing
Risk assessment (provider determining
your likelihood of having a mutation)
Information provided on BRCA1 and
BRCA2 genes and breast cancer
Psychological support
Information provided on
management/treatment for mutation
positive patients
Risk estimation for other family
members
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2

3
Neutral

4

5
Very
positive

17. Thinking back to when you received the results of your genetic testing, were you:
1
3
5
2
4
Not at all
Moderately
Extremely
Surprised?
Upset?
Relieved?
18. What actions did you take after you received your genetic testing results? Select
all that apply.
1. No action taken
2. Increased screening (mammograms, MRI, clinical exams, selfexams)
3. Communication of results to family members
4. Changing cancer treatment plan
5. Prophylactic surgery (mastectomy and/or salpingo-oophorectomy)
6. Other: _____________________
Page 7- DTC testing
In contrast to the traditional clinical testing experience, direct-to-consumer (DTC)
genetic testing refers to genetic testing that consumers can order from home, in many
cases without involvement from healthcare providers or insurance companies. These tests
allow consumers to access their own genetic information and learn more about their
genetic predisposition to certain traits and disease. Typically, consumers order DTC
genetic testing online or via telephone for a cost ranging from $99-250. A kit is then
mailed to the customer’s house, containing a container to collect saliva. The saliva
sample is then mailed back to the company. The customer’s results will be reported back
to them in the form of an online report. The report typically provides an interpretation of
what their genetic results mean for their health and susceptibility to disease. Historically,
DTC testing has been utilized to provide information about ancestry, disease risk (such as
heart disease or Parkinson’s disease), and carrier status for recessive genetic conditions
such as cystic fibrosis. More recently, the FDA has approved some companies to provide
DTC testing for cancer-related genes, such as BRCA1 and BRCA2. This allows any
person over the age of 18 to order genetic testing for BRCA1 and BRCA2 mutations from
anywhere in the country at any time, without having to involve a physician or other
healthcare provider. No referral or appointment is necessary to undergo DTC-genetic
testing for BRCA1 and BRCA2 mutations, and once results are available, the costumer
can access them any time.
Pre- and post-test genetic counseling is usually not included as part of the DTC
genetic testing experience. Those customers who wish to review their results with a
clinician, ask questions, or get referrals to other specialists must make those arrangements
on their own, and typically pay for the genetic counseling out-of-pocket.
In our study, we are interested in understanding the perspectives of BRCA1 and
BRCA2 mutation carriers who underwent the clinical testing experience through a
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physician or genetic counselor. We are interested in learning how you perceive direct-toconsumer genetic testing for BRCA1 and BRCA2 mutations.
19. Prior to reading the description above, had you heard of direct-to-consumer
(DTC) genetic testing?
i) Yes, I had heard of DTC genetic testing and I knew what the term meant
ii) Yes, I had heard of DTC genetic testing, but I did not know what the term
meant
iii) No, I had not heard of DTC genetic testing prior to this survey
20. Have you had DTC genetic testing before (such as 23andMe, Ancestry DNA)?
i) Yes
ii) No
21. Thinking about both DTC genetic testing and clinical genetic testing, if both
options had been equally accessible to you at the time you were considering
BRCA1 and BRCA2 mutation testing, which option would you have preferred?
For the purposes of this question, please assume that the accuracy of the genetic
test is the same whether ordered clinically or through a DTC genetic testing
company.
1- Definitely clinical testing
2- Probably clinical testing
3- Not sure
4- Probably DTC testing
5- Definitely DTC testing
Please explain why you chose this answer
22. Which aspects of DTC genetic testing do you see favorably compared to clinical
genetic testing? Please rate on a scale of 1 (very unfavorable) to 5 (very
favorable).
1
5
3
Very
Very
Same
unfavorable
2
4
favorable
as
compared
compared
clinical
to clinical
to clinical
Cost of DTC testing
Accessibility of DTC
testing
Time of DTC testing
Information/education
provided in DTC
testing
Psychosocial support
in DTC testing
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Page 8 – Scenarios
Please think back to your own genetic testing experience when answering the following
questions.
For the purposes of questions 1 through 4 below, please assume that the accuracy of the
genetic test is the same whether ordered clinically or through a DTC-GT company.
23. If there had been a 2+ month wait to schedule a clinical genetic testing appointment,
or you could have ordered DTC testing online immediately, which would you have
preferred?
1- Definitely clinical testing
2- Probably clinical testing
3- Not sure
4- Probably DTC testing
5- Definitely DTC testing
Please explain why you chose this answer
24. If you had to pay out-of-pocket for clinical genetic testing for BRCA1 and BRCA2
mutations ($250-400), or you could have ordered DTC BRCA1 and BRCA2 testing for
$99, which would you have preferred?
1- Definitely clinical testing
2- Probably clinical testing
3- Not sure
4- Probably DTC testing
5- Definitely DTC testing
Please explain why you chose this answer
25. If the nearest available clinic for BRCA1 and BRCA2 testing was a 2-hour drive,
would you choose to get tested in this clinic, or order DTC testing?
1- Definitely clinical testing
2- Probably clinical testing
3- Not sure
4- Probably DTC testing
5- Definitely DTC testing
Please explain why you chose this answer
26. If your children desired DTC testing rather than clinical testing to see if they have
your BRCA1 or BRCA2 mutation, would you support their decision?
1- Definitely would not support
2- Probably would not support
3- Neutral
4- Probably support
5- Definitely support
Please explain why you chose this answer
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27. For this question, imagine that DTC genetic testing of BRCA1 and BRCA2 can
detect mutations in 15% of individuals with a mutation. In other words, of 100 true
mutation carriers, 15 will receive a positive genetic testing result, while 85 will
receive an incorrect, negative result (a “false negative”). However, this testing would
be widely available to all interested individuals, and has the potential to detect
mutations in people who otherwise would not meet clinical testing criteria (e.g., they
haven’t had cancer themselves, or do not have a significant family history of cancer).
Also imagine that clinical genetic testing of BRCA1 and BRCA2 can detect mutations
in 95% of individuals with a mutation. In other words, of 100 true mutation carriers,
95 will receive a positive genetic testing result, while 5 will receive an incorrect, “false
negative” result. However, this testing is limited to those individuals who meet certain
criteria (e.g., have had early onset breast or ovarian cancer, or have a significant family
history of cancer); therefore, some people with mutations will never be tested and their
mutations would not be detected.
In this situation, if you could choose either DTC genetic testing or clinical genetic
testing for yourself, which option would you have chosen?
1- Definitely clinical testing
2- Probably clinical testing
3- Not sure
4- Probably DTC testing
5- Definitely DTC testing
Please explain why you chose this answer
28. Now imagine you have a friend who is concerned about her risk of breast cancer.
She could order DTC-GT, or she could ask her doctor for a referral for clinical genetic
testing. If she orders DTC-GT, she will definitely get testing, but it will only detect
15% of mutations. If she is referred to a clinic, she may not be offered genetic testing
(depending on whether or not she meets criteria), but if she is found to meet high-risk
criteria, then she would be offered testing that detects 95% of mutations. In this
situation, which type of testing would you recommend to your friend?
1- Definitely clinical testing
2- Probably clinical testing
3- Not sure
4- Probably DTC testing
5- Definitely DTC testing
Please explain why you chose this answer
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Page 9- Final questions
29. Overall, do you support DTC genetic testing for mutations in the BRCA1 and
BRCA2 genes being available to the general public?
1- Strongly against
2- Somewhat against
3- Neutral/not sure
4- Somewhat support
5- Strongly support
Please explain why you chose this answer
30. Are you concerned about people ordering DTC testing for BRCA1 and BRCA2
mutations without involvement from any healthcare provider?
1- Not concerned
2- Slightly concerned
3- Very concerned
4- Extremely concerned
5- Not sure/undecided
If you have concerns, please briefly describe them. If you do not have any concerns,
please explain why.
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